期刊
NATURE MEDICINE
卷 24, 期 7, 页码 908-922出版社
NATURE PORTFOLIO
DOI: 10.1038/s41591-018-0104-9
关键词
-
资金
- NIAAA NIH HHS [R01 AA020709, P20 AA017067] Funding Source: Medline
- NIDDK NIH HHS [R01 DK056621, R56 DK056621] Funding Source: Medline
There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD), paralleling a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum of liver abnormalities from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), has a variable course but can lead to cirrhosis and liver cancer. Here we review the pathogenic and clinical features of NAFLD, its major comorbidities, clinical progression and risk of complications and in vitro and animal models of NAFLD enabling refinement of therapeutic targets that can accelerate drug development. We also discuss evolving principles of clinical trial design to evaluate drug efficacy and the emerging targets for drug development that involve either single agents or combination therapies intended to arrest or reverse disease progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据